Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma - O’Reilly, E M; Lee, J W; Lowery, M A (Cancer, 2018)
et al.